Production and optimization of valproic acid nanostructured lipid carriers by the Taguchi design

Pharmaceutical Development and Technology

Volumn 15, Issue 1, 2010, Pages 89-96

  Varshosaz, Jaleh ^a   Eskandari, Sharareh ^a,b   Tabakhian, Majid ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b R and D Department of RAHA Pharmaceutical Company   (Iran)

Author keywords

Nano lipid carriers; Solvent diffusion method; Taguchi design; Valproic acid

Indexed keywords

ACETONE; ALCOHOL; NANOSTRUCTURED LIPID CARRIER; POLOXAMER; SOLID LIPID NANOPARTICLE; SURFACTANT; UNCLASSIFIED DRUG; VALPROIC ACID; ANTICONVULSIVE AGENT; DELAYED RELEASE FORMULATION; DRUG CARRIER; EMULSION; LIPID; NANOPARTICLE; POLYMER;

ARTICLE; NANOPHARMACEUTICS; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SUSTAINED DRUG RELEASE; ULTRASOUND; ZETA POTENTIAL; ADMINISTRATION AND DOSAGE; BRAIN; CHEMISTRY; DELAYED RELEASE FORMULATION; DIFFUSION; EMULSION; MEDICINAL CHEMISTRY; PARTICLE SIZE; SYNTHESIS;

ANTICONVULSANTS; BRAIN; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DIFFUSION; DRUG CARRIERS; EMULSIONS; LIPIDS; NANOPARTICLES; PARTICLE SIZE; POLYMERS; SURFACE-ACTIVE AGENTS; VALPROIC ACID;

EID: 76749114292     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450903013568     Document Type: Article

References (55)

1. Levy RH, Shen DD. Valproate: Absorption, distribution, and excretion. In: Levy RH, Dreifuss FE, Mattson RH, Meldrum BS, Penry JK, editors. Antiepileptic drugs. 3rd ed. New York: Raven Press; 1989:583-599.
2. Radatz M, Nau H. Toxicity. In: Löscher W. editor. Milestones in drug therapy: Valproate. Basel: Birkhauser Verlag; 1999:91-128.
3. Gibbs PJ, Moji CA, Ziping Y, Shen DD. Valproic acid uptake by bovine brain microvessel endothelial cells: role of active efflux transport. Epilepsy Res 2004;58:53-66.
4. Vainionpää LK, Rättyä J, Knip M, Tapanainen JS, Pakarinen AJ, Lanning P, Tekay A, Myllylä VV, Isojärvi JI. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann Neurol 1999;45:444-450.
5. Kakee A, Hitomi T, Hosoya K, Sugiyama Y, Terasaki T. In vivo evidence for brain-to-blood efflux transport of valproic acid across the blood-brain barrier. Microvasc Res 2002;63:233-238. (Pubitemid 34971640)
6. Scism JL, Powers KM, Artru AA, Lewis L, Shen DD. Probenecidinhibitable efflux transport of valproic acid in the brain parenchymal cells of rabbits: A microdialysis study. Brain Res 2000;884:77-86.
7. Stouch TR, Gudmundsson O. Progress in understanding the structure-activity relationships of P-glycoprotein. Adv Drug Del Rev 2002;54:315-328.
8. Miller DS, Graeff C, Droulle L, Fricker S, Fricker G. Xenobiotic efflux pumps in isolated fish brain capillaries. Am J Physiol Reg 2002;51:191-198.
9. Kabanov AV, Batrakova EV, Miller DW. Pluronic block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier. Adv Drug Del Rev 2003;55:151-164.
10. Müller RH, Maeder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000;50:161-177.
11. Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Del Rev 2002;54:S131-155.
12. Pouton CW. Lipid formulations for oral administration of drugs: Non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur J Pharm Sci 2000;11:S93-98.
13. Müller RH. Lipid nanoparticles: recent advances. Adv Drug Del Rev 2007;59:375-376.
14. Beduneaua A, Saulniera P, Benoit JP. Active targeting of brain tumors using nanocarriers. Biomaterials 2007;28:4947-4967.
15. Illum L. Nasal drug delivery - possibilities, problems and solutions. J Control Rel 2003;87:187-198. (Pubitemid 36255456)
16. Fechter LD, Johnson DL, Lynch RA. The relationship of particle size to olfactory nerve uptake of a non-soluble form of manganese into brain. Neurotoxicology 2002;23:177-183.
17. Greer CA, Margolis F, Ennis M, Shipley MT. Ultrastructural characteristics and conduction velocity of olfactory receptor neuron axons in the olfactory marker protein-null mouse. Brain Res 2000;866:227-236.
18. Joresa K, Mehnerta W, Drechslerb M, Bunjesc H, Johannd C, Maeder K. Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. J Control Rel 2004;95:217-227.
19. Taguchi G, Konishi S. Orthogonal arrays and linear graphstools for quality engineering, American Supplier Institute Inc., Dearborn, Michigan; 1987.
20. Fowlkes WY, Creveling CM. Engineering methods for robust product design using Taguchi Methods® in technology and product development. New York: Addison-Wesley; 1995.
21. Kishore P, Rajani Kumar V, Satyanarayana V, Krishna DR. HPLC determination of valproic acid in human serum. Pharmazie 2003;58:378-380.
22. Venkateswarlu V, Manjunath K. Preparation characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Rel 2004;95:627-638.
23. Hu FQ, Zhang Y, Du YZ, Yuan H. Nimodipine loaded lipid nanospheres prepared by solvent diffusion method in a drug saturated aqueous system. Int J Pharm 2008;348:146-152.
24. Mehnert W, Maeder K. Solid lipid nanoparticles production, characterization and applications. Adv Drug Del Rev 2001;47:165-196.
25. Magalha NSS, Pontes A, Pereira VMW, Caetano MNP. Colloidal carriers for benzathine penicillin G: Nanoemulsions and nanocapsules. Int J Pharm 2000;208:71-80.
26. Jenning V, Thünemann AF, Gohla SH. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm 2000;199:167-177. (Pubitemid 30236188)
27. Müller RH, Jenning V, Maeder K, Lippacher A. Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same. European Patent 2002;1176949.
28. Baschong W, Mongiat S, OCHS D. Glucan compositions. World Patent; 2007:062995.
29. Jenning V, Maeder K, Gohla SH. Solid lipid nanoparticles (SLN) based on binary mixtures of liquid and solid lipids: A 1H-NMR study. Int J Pharm 2000;205:15-21. (Pubitemid 30734720)
30. Saupe A, Gordon KC, Rades T. Structural investigations on nanoemulsions, solid lipid nanoparticles and nanostructured lipid carriers by cryo-field emission scanning electron microscopy and Raman spectroscopy. Int J Pharm 2006;314:56-62.
31. Bouchemal K, Briançon S, Perrier E, Fessi H. Nano-emulsion formulation using spontaneous emulsification: Solvent, oil and surfactant optimization. Int J Pharm 2004;280:241-251.
32. Schubert MA, Müller-Goymann CC. Solvent injection as a new approach for manufacturing lipid nanoparticles - evaluation of the method and process parameters. Eur J Pharm Biopharm 2003;55:125-131.
33. Schwarz C, Mehnert W, Lucks JS, Müller RH. Solid lipid nanoparticles (SLN) for controlled drug delivery I. Production, characterization and sterilization. J Control Rel 1994;30:83-96.
34. Reddy LH, Murthy R. Etoposide-loaded nanoparticles made from glyceride lipids: formulation, characterization, in vitro drug release, and stability evaluation. AAPS Pharmscitech 2005;6:Article 24.
35. Ye J, Wang Q, Zhoua X, Zhang N. Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis. Int J Pharm 2008;352:273-279.
36. Saulnier P, Pech B, Proust JE, Benoit JP. Physico-chemical stability of colloidal lipid particles. Biomaterials 2003;24:4283-4300.
37. Teixeira M, Alonso MJ, Pinto MMM, Barbosa CM. Development and characterization of PLGA nanospheres and nanocapsules containing xanthone and 3-methoxyxanthone. Eur J Pharm Biopharm 2005;59:491-500.
38. Mitra A, Lin S. Effect of surfactant on fabrication and characterization of paclitaxel-loaded polybutylcyanoacrylate nanoparticulate delivery systems. J Pharm Pharmacol 2003;55:895-902.
39. Zimmermann E, Müller RH. Electrolyte-and pH-stabilities of aqueous solid lipid nanoparticle (SLN) dispersions in artificial gastrointestinal media. Eur J Pharm Biopharm 2001;52:203-210.
40. Hong Y, Wang LL, Du Yz, Jian Y, Hu FQ, Su Z. Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification. Colloid Surface B 2007;60:174-179.
41. Mosqueira VC, Legrand P, Morgat JL, et al. Biodistribution of long-circulating PEG-grafted nanocapsules in mice: Effects of PEG chain length and density. Pharm Res 2001;18:1411-1419.
42. Freitas C, Müller RH. Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN) dispersions. Int J Pharm 1998;168:221-229. [My paper]
43. Jiesheng Y, Qung W, Xuefeng Z, Na Z. Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis. Int J Pharm 2008;352:273-279.
44. Heurtault B, Saulnier P, Pech B, et al. The influence of lipid nanocapsule composition on their size distribution. Eur J Pharm Sci 2003;18:55-61.
45. Souto EB, Wissing SA, Barbosa CM, Müller RH. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm 2004;278:71-77.
46. Reddy LH, Vivek K, Bakshi N, Murthy RS. Tamoxifen citrate loaded solid lipid nanoparticles (SLN): Preparation, characterization, in vitro drug release, and pharmacokinetic evaluation. Pharm Dev Technol 2006;11:167-177.
47. Teeranachaideekul V, Souto EB. Junyaprasert VB., Müller RH. Cetyl palmitate-based NLC for topical delivery of Coenzyme Q10 - development, physicochemical characterization and in vitro release studies. Eur J Pharm Biopharm 2007;67:141-148.
48. Üner M, Wissing SA, Yener G, Müller RH. Skin moisturizing effect and skin penetration of ascorbyl palmitate entrapped in solid lipid nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) incorporated into hydrogel. Pharmazie 2005;60:751-755.
49. Souto EB, Müller RH, Gohla S. A novel approach based on lipid nanoparticles (SLN® ) for topical delivery of α-lipoic acid. J Microencapsul 2005;22:581-592.
50. Souto EB, Müller RH. SLN and NLC for topical delivery of ketoconazole. J Microencapsul 2005;22:501-510.
51. Souto EB, Müller RH. The use of SLN® and NLC® as topical particulate carriers for imidazole antifungal agents. Pharmazie 2006;61:431-437.
52. Castelli F, Puglia C, Sarpietro MG, Rizza L, Bonina F. Characterization of indomethacin-loaded lipid nanoparticles by differential scanning calorimetry. Int J Pharm 2005;304:231-238.
53. Kumara VV, Chandrasekar D, Ramakrishna S, Kishan V, Raoa YM, Diwan PV. Development and evaluation of nitrendipine loaded solid lipid nanoparticles: Influence of wax and glyceride lipids on plasma pharmacokinetics. Int J Pharm 2007;335:167-175.
54. Müller RH, Olbrich C. Solid lipid nanoparticles phagocytic uptake, in vitro cytotoxicity and in vitro biodegradation. Pharm Ind 1999;61:564-569. (Pubitemid 29336629)
55. Olbrich C, Müller RH. Enzymatic degradation of SLN - effect of surfactant and surfactant mixtures. Int J Pharm 1999;180:31-39.